-
Tesla and
CureVac filed a
joint patent on the technology. In August, Musk
reviewed the
project with
Curevac while in Germany. By 2017,
CureVac had received...
- The
CureVac COVID-19
vaccine (abbreviated CVnCoV) was a COVID-19
vaccine candidate developed by
CureVac N.V. and the
Coalition for
Epidemic Preparedness...
-
concerning the use of RNA and is a
founder of the
German biotechnology company CureVac. He
created the
initial technology used in RNA
vaccines and has reportedly...
-
additional companies such as
Viacyte (part of Vertex), Nkarta, Capsida,
Curevac, and others.
CRISPR Therapeutics has
drugs approved and in development...
- CSL; 1904– ) CSPC
Pharmaceutical Group (1992- ) CSPC
Zhongrun (1989– )
CureVac (2000– )
CytRx (1985– )
Daiichi Sankyo (2005– )
Debiopharm (1979– ) Dechra...
- or the
Walvax COVID-19
vaccine used in
Indonesia (and the now
abandoned CureVac vaccine candidate, as well), do not have such requirements. In RNA therapeutics...
-
including Deutsche Post,
Deutsche Telekom, Commerzbank, Lufthansa, and
CureVac. In 2013, KfW
agreed to help
establish a
Portuguese financial institution...
- Oxford-AstraZeneca at €1.78;
Johnson &
Johnson at $8.50, Sanofi-GSK at €7.56,
CureVac at €10, and
Moderna at $18. In the same month,
Israel ordered 8 million...
- (€955 million). In July 2020, GSK
acquired a 10%
stake in
German biotech company CureVac. In
March 2018, GSK
announced that it has
reached an
agreement with Novartis...
-
patent on Moderna's mRNA
vaccine technology, are ongoing. DNA
vaccine CureVac "Moderna, Inc., 2023, Form 10-K
Annual Report". U.S.
Securities and Exchange...
